Sales and Marketing

Showing 15 posts of 11527 posts found.

Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma

March 3, 2020 Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma

Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …

Funding overview for the pharmaceutical industry and outlook for 2020

March 2, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2020, M&A, MA, feature, mergers & acquisitions, opinion, pharma

This article was originally published in the January/February 2020 issue of Pharmafocus.With the advent of a New Year, Michael Jewell, …

GW Pharma takes back control of UK Sativex sales from Bayer

March 2, 2020 Sales and Marketing Bayer, GW Pharma, Sativex, UK

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …

UK Health Secretary says no tactics will be “off the table” in dealing with coronavirus

March 2, 2020 Sales and Marketing Chinese Coronavirus, MERS, Sars, Wuhan Coronavirus, coronavirus

British Health Secretary Matt Hancock has said nothing will be “off the table” in tackling the coronavirus as cases in …

FDA approves first generic version of Shkreli-hiked toxoplasmosis drug Daraprim

March 2, 2020 Sales and Marketing Cerovene, Daraprim, FDA, Martin Shkreli, generics, pharma

The FDA has awarded approval to the first generic medicine for the treatment of toxoplasmosis, authorising Cerovene’s version of Daraprim …

Sanofi set to pay $11.9 million to resolve kickback probe, US Justice Department announces

March 2, 2020 Sales and Marketing Co pays, Justice department, Medicaid, Medicare, Sanofi, insurance

The Justice Department have announced that Sanofi SA have agreed to pay $11.85 million to resolve allegations it used a …

Experimental drug could treat dyskinesia in people with Parkinson’s

March 2, 2020 Sales and Marketing Parkinson's, Parkinson's disease, dyskinesia, spasms

Results from a new study researching treatment for dyskinesia has offered hope that it may be treatable in people with …

Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s

February 28, 2020 Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab

Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …

Top Ten most popular articles on Pharmafile.com this week

February 28, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chinese Coronavirus, Johnson and Johnson, Wuhan Coronavirus, coronavirus

The coronavirus continues to spread across the globe as the US launch their first trials for Gilead’s ebola drug remdesivir …

Acacia Pharma secures first FDA approval with Barhemsys for postoperative nausea and vomiting

February 28, 2020 Medical Communications, Sales and Marketing Acacia, FDA, UK, US, pharma

UK-based Acacia Pharma has secured its first US approval with the FDA’s decision to authorise Barhemsys (amisulpride injection) for the …

The March 2020 issue of Pharmafocus is available to read free online now!

February 27, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing England, Pharmafocus, UK, mumps, pharma, pharmacovigilance, type 2 diabetes

The latest monthly edition of Pharmafocus, the March issue, is available to read for free online now! The coronavirus continues …

FDA advisory committee narrowly backs Eli Lilly’s Cyramza combo for metastatic EGFR+ NSCLC

February 27, 2020 Sales and Marketing Eli Lilly, FDA, cyramza, pharms

Eli Lilly’s Cyramza (ramucirumab) has edged closer to US approval after it scored a recommendation from the FDA’s Oncologic Drugs …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma

February 27, 2020 Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …

NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma

February 26, 2020 Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche

It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …

Scotland’s life sciences sector on track to break $8 billion by 2025

February 25, 2020 Manufacturing and Production, Sales and Marketing Scotland, UK, life sciences, pharma

A new report from the Scottish Government has revealed that the country’s life sciences sector is on track to breeze …
The Gateway to Local Adoption Series

Latest content